Intravascular malignant lymphocytosis (IML) is a rare systemic disease characterized by proliferation of malignant B (rarely T) lymphoid cells within the lumina of small arteries, veins, and capillaries. Diagnosis requires skin, liver, renal, meningeal, or brain biopsy, but is rarely made ante mortem. In this report, we describe a patient who had an ante mortem diagnosis of IML as a result of a skin biopsy. Autologous peripheral blood stem cell transplantation (auto-PBSCT) was successfully performed after chemotherapy. The patient has survived for more than 30 months since the onset of the disease and maintains complete remission on the 450th day post PBSCT. To our knowledge, this is the first case of IML treated by auto-PBSCT. Bone Marrow Transplantation (2001) 27, 1101-1103. Keywords: intravascular malignant lymphocytosis (IML); skin biopsy; CHOP; auto-PBSCT
A 52-year-old man presented to our hospital in September 1998 with a 9-month history of progressive dementia, hemiparesia, urinary retention, and weight loss. Hasegwa dementia scale (HDS) , that is the scale to evaluate the degree of dementia, was 12 point. He had reddish indurated macules scattered over the anterior chest surface. Routine hematological, biochemical and serological values were all within normal limits. Examination of bone marrow showed no abnormal cells. Magnetic resonance imaging (MRI) of the brain demonstrated an increased periventricular signal on T2-weighted images. Computed tomography (CT) scans of the brain disclosed low density areas in the corresponding section. Positron emission tomography of the brain showed degraded blood flow in the left temporal and frontal lobe and right cerebellum. Results of bone marrow biopsy, cerebrospinal fluid examination, CT scans of chest and abdomen, abdominal ultrasound sonography and whole body gallium scintigram were normal. A skin biopsy specimen of the anterior chest eruption revealed atypical hyperchromatic large lymphoid cells within the lumena of capillary vessels. These cells also infiltrated the extravascular spaces. Immunohistochemical study showed that these cells were positive for a B cell marker L26 (CD20), but not for a T cell marker MT-l (CD43) nor endothelial cell marker (CD34). DNA obtained from these cells and bone marrow cells at the time of lymphoma diagnosis showed no immunoglobulin gene rearrangements by reverse transcription polymerase chain reaction (RT-PCR). In addition, the serum soluble interleukin 2 receptor (s-IL2R) value was elevated to 1610 U/ml. Based on the results stated above a diagnosis of IML (B cell type) was established.
The clinical course is shown in Figure 1 . The patient was treated with a standard regimen comprising doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP). Amnesia, hallucinations, dementia and skin macules regressed after one cycle and the patient achieved a complete response after three cycles, although urinary incontinence and hemiparesis remained. Positron emission tomography of the brain showed normal blood flow. Because most previously reported cases have shown limited response to therapy in patients with IML and survival rates have been discouragingly low, 1,2 mega-dose chemotherapy followed by autologous PBSCT was planned. PBSC were mobilized by etoposide (500 mg/m 2 ) for 3 consecutive days and granulocyte colony-stimulating factor (lenograstim: 1.25 g/kg) for 8 consecutive days. Subsequently, the patient received five more cycles of CHOP chemotherapy. PBSCT was performed 6 months after diagnosis. Transfusion of 6.4 × 10 6 /kg CD34-positive cells followed a conditioning regimen consisting of ranimustine (MCNU), 300 mg/m 2 , days −8 and −3; carboplatin (CBCDA), 500 mg/m 2 , days −7 and −6; etoposide, 1000 mg/m 2 , days −6 to −4; and cyclophosphamide 1800 mg/kg, days −3 and −2. Rapid trilineage engraftment was observed. The neutrophil count exceeded 0.5 × 10 9 /l on day 9, and was 20 × 10 9 /l on day 12. All therapy was well tolerated and the patient was discharged from hospital on day 87. MRI of the brain after PBSCT Bone Marrow Transplantation showed none of the abnormal findings found before treatment, and the skin macules had not recurred. He remains in complete remission with no evidence of disease 14 months after PBSCT.
Discussion
Since IML is a special type of non-Hodgkin's lymphoma that may involve multiple organs, systemic chemotherapy such as CHOP, and in some cases additional radiotherapy, may be indicated. However, until recently few cases were diagnosed ante mortem. Even in the cases diagnosed ante mortem and treated with chemotherapy, complete remission and long-term disease-free survival did not occur, with few exceptions. The failure of chemotherapy and poor prognosis in most patients may be related to long delays in diagnosis, 3 especially when neurological involvement is the prominent feature. If this hypothesis is correct, earlier diagnosis may lead to more aggressive therapeutic interventions and higher rates of complete remission may be achieved.
Another explanation is that the malignant cells of this disease are less sensitive to chemotherapy than those of other lymphomas. If this hypothesis is correct, a strong induction regimen like CHOP or biweekly CHOP is essential 4 and consolidation therapy with stem cell transplantation may be as desirable as in the therapy of other aggressive non-Hodgkin's lymphomas.
Rose et al 5 reported the case of a patient with IML who was treated with autologous bone marrow transplantation. They recommended use of marrow as the source of rescue rather than CD34-positive cells because of the inability of the lymphoma cells to extravasate and the peculiar localization of this strange lymphoma.
Bone marrow involvement has been reported to be uncommon in patients with IML, but recently some authors have reported bone marrow invasion in patients with this disease.
6-10 Estalilla et al 6 reported five cases, initially diagnosed by bone marrow biopsy, and speculated that involvement of bone marrow and peripheral blood might be more common than has been reported in the literature.
In our case, although histologic evidence of IML was not detected in bone marrow, malignant lymphocytes extravasated into the perivascular spaces. Hashizume reported liver substance involvement in five of six patients with IML. 9 With regard to the possibility of extravasation, notably bone marrow involvement and quick hematopoietic recovery generally recognized in PBSCT, we hypothesized that it was reasonable to choose CD34-positive cells for rescue after mega-dose chemotherapy, which is similar to treatment of other high risk lymphomas.
Although IML has been thought to be a rare disease, more cases will be discovered with increased awareness of this disease and appropriate biopsies. Effective treatment must be established as soon as possible. In the case reported here, we successfully treated the patient with IML by megadose chemotherapy and PBSCT. We speculate that megadose chemotherapy followed by progenitor cell rescue may provide optimal therapy for patients with IML. More cases diagnosed early are required to determine the best indication and method of the treatment of this disease.
